(CercleFinance.com) – Bristol Myers presented data this weekend from a phase 3 trial evaluating the subcutaneous formulation of Opdivo (nivolumab) versus intravenous (IV) Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) having received prior systemic therapy.
The study shows that the subcutaneous Opdivo formulation demonstrated ‘non-inferiority’ compared to IV Opdivo.
‘Having the ability to administer immunotherapy subcutaneously could undoubtedly reduce the treatment burden that patients diagnosed with cancer currently face, as well as help maximize the efficiency of healthcare systems’, believes Saby George, professor of oncology and medicine, director of Clinical Trials Network, Department of Medicine, Roswell Park Comprehensive Cancer Center.
He says these findings have the potential to change practice and improve patients’ treatment experience with an injection that can be administered in less than five minutes and, in some cases, outside of the infusion center.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
